Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ingeborg M M van Leeuwen

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Oncotarget|June 20, 2012
Cyclotherapy: opening a therapeutic window in cancer treatmentIngeborg M M van Leeuwen
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|October 6, 2010
Dynamic energy budget approaches for modelling organismal ageingIngeborg M M van Leeuwen, Julio Vera, Olaf Wolkenhauer
Water Research|November 8, 2003
A general model for multiple substrate biodegradation. Application to co-metabolism of structurally non-analogous compoundsBernd W Brandt, Ingeborg M M van Leeuwen, Sebastiaan A L M Kooijman
World Journal of Gastroenterology|April 26, 2007
Towards a multiscale model of colorectal cancerIngeborg M M van Leeuwen, Carina M Edwards, Mohammad Ilyas, et al.
Cell Cycle (Georgetown, Tex.)|April 21, 2012
An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cellsIngeborg M M van Leeuwen, Bhavya Rao, Marijke C C Sachweh, et al.
Journal of Theoretical Biology|March 27, 2007
Elucidating the interactions between the adhesive and transcriptional functions of beta-catenin in normal and cancerous cellsIngeborg M M van Leeuwen, Helen M Byrne, Oliver E Jensen, et al.
Water Research|February 11, 2004
Modelling microbial adaptation to changing availability of substratesBernd W Brandt, Fleur D L Kelpin, Ingeborg M M van Leeuwen, et al.
Oncotarget|February 15, 2011
Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapyBhavya Rao, Ingeborg M M van Leeuwen, Maureen Higgins, et al.
Molecular Cancer Therapeutics|February 19, 2013
Modulation of p53 C-terminal acetylation by mdm2, p14ARF, and cytoplasmic SirT2Ingeborg M M van Leeuwen, Maureen Higgins, Johanna Campbell, et al.
Cell Cycle (Georgetown, Tex.)|April 15, 2011
Mechanism-specific signatures for small-molecule p53 activatorsIngeborg M M van Leeuwen, Maureen Higgins, Johanna Campbell, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Oncotarget|June 20, 2012
Cyclotherapy: opening a therapeutic window in cancer treatmentIngeborg M M van Leeuwen
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|October 6, 2010
Dynamic energy budget approaches for modelling organismal ageingIngeborg M M van Leeuwen, Julio Vera, Olaf Wolkenhauer
Water Research|November 8, 2003
A general model for multiple substrate biodegradation. Application to co-metabolism of structurally non-analogous compoundsBernd W Brandt, Ingeborg M M van Leeuwen, Sebastiaan A L M Kooijman
World Journal of Gastroenterology|April 26, 2007
Towards a multiscale model of colorectal cancerIngeborg M M van Leeuwen, Carina M Edwards, Mohammad Ilyas, et al.
Cell Cycle (Georgetown, Tex.)|April 21, 2012
An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cellsIngeborg M M van Leeuwen, Bhavya Rao, Marijke C C Sachweh, et al.
Journal of Theoretical Biology|March 27, 2007
Elucidating the interactions between the adhesive and transcriptional functions of beta-catenin in normal and cancerous cellsIngeborg M M van Leeuwen, Helen M Byrne, Oliver E Jensen, et al.
Water Research|February 11, 2004
Modelling microbial adaptation to changing availability of substratesBernd W Brandt, Fleur D L Kelpin, Ingeborg M M van Leeuwen, et al.
Oncotarget|February 15, 2011
Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapyBhavya Rao, Ingeborg M M van Leeuwen, Maureen Higgins, et al.
Molecular Cancer Therapeutics|February 19, 2013
Modulation of p53 C-terminal acetylation by mdm2, p14ARF, and cytoplasmic SirT2Ingeborg M M van Leeuwen, Maureen Higgins, Johanna Campbell, et al.
Cell Cycle (Georgetown, Tex.)|April 15, 2011
Mechanism-specific signatures for small-molecule p53 activatorsIngeborg M M van Leeuwen, Maureen Higgins, Johanna Campbell, et al.
Pageof 2